Dementia Drugs Market Benefit and Volume 2018 with Status and Prospect to 2026
Dementia is one of
the most prevalent neurodegenerative diseases in which patients
suffer from various behavioral changes, as a primary symptoms such as
decline in memory or other thinking skills and can gets worse as
condition progresses. It majorly affects people of aged 65 years and
above. Currently, there is no curative therapy available for dementia
disease. However, drugs for dementia therapy are in pipeline, which
are expected to be launched in the near future, in turn propelling
growth of the dementia drugs market.
Get Exclusive
Sample Report at: http://bit.ly/2xhbkPz
Market Dynamics
Increasing aging
population along with its associated complications is the major
driving factor for growth of the dementia drugs market. For instance,
according to Centers of Disease Control and Prevention (CDC), 2013,
five million people were suffering from AD and the number is expected
to rise up to 14 million by 2050, in the U.S. Moreover, according to
World Health Organization (WHO), 2017, around 47 million people
suffer from dementia and around 10 million new cases are reported
annually. Increasing incidence of dementia coupled with growing
demand for therapy is expected to favor growth of the dementia drugs
market in the near future. According to Australian Institute of
Health and Welfare (AIHW) estimates, the number of people with
dementia is expected to reach to around 400,000 by 2020, and around
900,000 by 2050. Moreover, the National Health and Medical Research
Council (NHMRC) is working in collaboration with the Australian
Research Council (ARC) to prioritize and fund new dementia research
projects and translate research to improve prevention, diagnosis,
treatment, and care for dementia patients.
Increasing number
of pipeline products is expected to drive growth of the dementia
drugs market
Major factors
fueling growth of the dementia drugs market include the large number
of drugs in the pipeline, which are expected to enter into the market
by 2020-2022. According to the study published by Translational
Research and Clinical Intervention, in September 2017, it is recorded
that 105 new drugs in pipeline, out of which 25 are in phase one, 52
in phase two and 28 are in phase three. These new products use novel
approaches such as immunotherapy to target amyloid beta, beta-site
amyloid precursor protein cleaving enzyme 1 inhibitors, tau
aggregation inhibitor, and serotonin 5-HT6 receptor antagonist.
Furthermore, increasing collaborations amongst companies for
developing drugs in joint efforts is also boosting growth of the
market. For instance, in November 2017, Novartis and Amgen, along
with the Banner Alzheimer's Institute, announced a collaboration to
assess potential of the BACE1 inhibitor CNP520 to prevent or delay
symptoms of Alzheimer's disease. However, failure of investigational
candidate in late stage is expected to be a huge setback in the
current Alzheimer’s drugs market. For instance, in February 2017,
an external data monitoring committee warned that Merck & Co.,
Inc. terminated study of Alzheimer's candidate verubecestat due to
potential failure in a Phase II/III study.
Increasing incidence
of Alzheimer’s disease worldwide is expected to drive growth of the
dementia drugs market. According to World Alzheimer Report in 2016,
around 46.5 million people were suffering from Alzheimer’s disease,
the number for which is projected to reach 50 million by 2017.
Increasing geriatric population is also a major risk factor for
growing incidence of Alzheimer’s disease, which in turn boosts
growth opportunity for dementia drugs market. For instance, according
to World Population Prospects (WPP) published by United Nations in
2017, around 962 million people aged 60 years and above were
recorded, which accounted for 13 percent of the global population.
The number is projected to reach 1.4 billion by 2030, exhibiting
annual growth rate of 3 percent. Europe accounts for the largest
geriatric population (25% of population) in 2017, Asia Pacific also
had geriatric population of 547 million people in 2017 and it is
projected to reach 900 million by 2025. These regions thus show
potential opportunity for growth of the market.
Dementia Drugs
Market Regional Outlook - Growing Integration of Healthcare and IT to
boost demand in emerging economies
On the basis of
geography, the global dementia drugs market can be segmented into six
major regions: North America, Europe, Asia Pacific, Latin America,
Middle East, and Africa. North America is expected to hold the
largest market, owing to major approval of drugs in this region and
favorable reimbursement scenarios. Asia Pacific is expected to emerge
as a major market in the near future, majorly due to the growing
geriatric population and Alzheimer’s disease cases, especially in
China, India. This in turn, is expected to create lucrative
opportunities for growth of the market. For instance, according to
Alzheimer’s Disease International Association, in 2015, East Asia
is the region with the maximum number of people living with dementia
(9.8 million), followed by Western Europe (7.4 million).
Key players are
adopting strategic collaborations and acquisitions and product
portfolio expansion to accelerate delivery of products and overall
revenue. For instance, Teva Pharmaceutical Industries Ltd. acquired
Actavis Generics from Allergan in 2016, for around US$ 40 billion,
which also includes the Alzheimer’s portfolio of Actavis Generics.
This acquisition boosted revenue of Teva in its fourth quarter of
2016 and first quarter of 2017. Furthermore, Genentech and AC Immune
are also jointly developing anti-amyloid beta antibody crenezumab,
which started phase three clinical trial in 2017. They are developing
anti-amyloid beta vaccine for Alzheimer’s disease treatment.
Furthermore, AC immune and Janssen Pharmaceutical are also
co-developing vaccine for Alzheimer’s treatment.
Inquire Here
Before Purchase of Research Report @ http://bit.ly/2MVAnSz
Some of the top
companies operating in the dementia drugs market are Eisai, Inc.,
Janssen Pharmaceuticals, Inc., Biogen Pharmaceuticals, Forest
Laboratories, Inc., Eli Lilly and Company, Novartis AG, Sanofi S.A.,
AstraZeneca GmbH, F. Hoffmann-La Roche, Merck & Co., Inc..,
Valeant Pharmaceutical International, Pfizer Inc., and Teva
Pharmaceuticals Industries Ltd.
About Coherent
Market Insights
Coherent Market
Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis,
consulting services, and competitive analysis through various
recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market
Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Comments
Post a Comment